Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. | Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Aplin C, Zielinski KA, Pabit S, Ogunribido D, Katt WP, Pollack L, Cerione RA, Milano SK., Free PMC Article | 08/23/2024 |
Structural and mechanistic analysis of Ca[2+]-dependent regulation of transglutaminase 2 activity using a Ca[2+]-bound intermediate state. | Structural and mechanistic analysis of Ca(2+)-dependent regulation of transglutaminase 2 activity using a Ca(2+)-bound intermediate state. Sewa AS, Besser HA, Mathews II, Khosla C., | 07/28/2024 |
Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors. | Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors. Buccarelli M, Castellani G, Fiorentino V, Pizzimenti C, Beninati S, Ricci-Vitiani L, Scattoni ML, Mischiati C, Facchiano F, Tabolacci C., Free PMC Article | 05/15/2024 |
The Role of Transglutaminase 2 in Cancer: An Update. | The Role of Transglutaminase 2 in Cancer: An Update. Zaltron E, Vianello F, Ruzza A, Palazzo A, Brillo V, Celotti I, Scavezzon M, Rossin F, Leanza L, Severin F., Free PMC Article | 03/14/2024 |
Prognostic significance of RKIP, TGM2, and CMTM4 expression in oral squamous cell carcinoma. | Prognostic significance of RKIP, TGM2, and CMTM4 expression in oral squamous cell carcinoma. Luo T, Xu T, Ou Y, Ci H, Sun J., Free PMC Article | 02/21/2024 |
Study of tissue transglutaminase spliced variants expressed in THP-1 derived macrophages exhibiting distinct functional phenotypes. | Study of tissue transglutaminase spliced variants expressed in THP-1 derived macrophages exhibiting distinct functional phenotypes. Arbildi P, Calvo F, Macías V, Rodríguez-Camejo C, Sóñora C, Hernández A. | 12/20/2023 |
Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target. | Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target. Malkomes P, Lunger I, Oppermann E, Lorenz J, Faqar-Uz-Zaman SF, Han J, Bothur S, Ziegler P, Bankov K, Wild P, Bechstein WO, Rieger MA., Free PMC Article | 10/26/2023 |
Transglutaminase 2 expression is associated with increased risk of lymph node metastasis and recurrence in papillary thyroid cancer. | Transglutaminase 2 expression is associated with increased risk of lymph node metastasis and recurrence in papillary thyroid cancer. Goksoy Solak Y, Yegen G, Onder S, Tekin S, Soyluk O, Gul N, Tanakol R, Aral F, Kubat Uzum A. | 10/23/2023 |
Expression of transglutaminase 2 in human gut epithelial cells: Implications for coeliac disease. | Expression of transglutaminase 2 in human gut epithelial cells: Implications for coeliac disease. Amundsen SF, Stamnaes J, Lundin KEA, Sollid LM., Free PMC Article | 10/20/2023 |
Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis. | Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis. Das S, Stamnaes J, Kemppainen E, Hervonen K, Lundin KEA, Parmar N, Jahnsen FL, Jahnsen J, Lindfors K, Salmi T, Iversen R, Sollid LM., Free PMC Article | 09/7/2023 |
Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype. | Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype. Chen X, Adhikary G, Newland JJ, Xu W, Keillor JW, Weber DJ, Eckert RL. | 09/6/2023 |
Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines. | Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines. Atobatele AG, Tonoli E, Vadakekolathu J, Savoca MP, Barr M, Kataria Y, Rossanese M, Burhan I, McArdle S, Caccamo D, Verderio EAM., Free PMC Article | 05/11/2023 |
A long non-coding RNA that harbors a SNP associated with type 2 diabetes regulates the expression of TGM2 gene in pancreatic beta cells. | A long non-coding RNA that harbors a SNP associated with type 2 diabetes regulates the expression of TGM2 gene in pancreatic beta cells. González-Moro I, Rojas-Márquez H, Sebastian-delaCruz M, Mentxaka-Salgado J, Olazagoitia-Garmendia A, Mendoza LM, Lluch A, Fantuzzi F, Lambert C, Ares Blanco J, Marselli L, Marchetti P, Cnop M, Delgado E, Fernández-Real JM, Ortega FJ, Castellanos-Rubio A, Santin I., Free PMC Article | 02/27/2023 |
Type 2 transglutaminase in the nucleus: the new epigenetic face of a cytoplasmic enzyme. | Type 2 transglutaminase in the nucleus: the new epigenetic face of a cytoplasmic enzyme. Rossin F, Ciccosanti F, D'Eletto M, Occhigrossi L, Fimia GM, Piacentini M., Free PMC Article | 02/4/2023 |
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. | Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J, Xu Z., Free PMC Article | 01/28/2023 |
The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype. | The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype. Chen X, Adhikary G, Newland JJ, Xu W, Ma E, Naselsky W, Eckert RL., Free PMC Article | 12/24/2022 |
Tissue transglutaminase activates integrin-linked kinase and beta-catenin in ovarian cancer. | Tissue transglutaminase activates integrin-linked kinase and β-catenin in ovarian cancer. Condello S, Prasad M, Atwani R, Matei D., Free PMC Article | 09/17/2022 |
Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy. | Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy. Paolella G, Sposito S, Romanelli AM, Caputo I., Free PMC Article | 08/13/2022 |
The Outside-In Journey of Tissue Transglutaminase in Cancer. | The Outside-In Journey of Tissue Transglutaminase in Cancer. Sima LE, Matei D, Condello S., Free PMC Article | 06/18/2022 |
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype. | Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype. Naselsky W, Adhikary G, Shrestha S, Chen X, Ezeka G, Xu W, Friedberg JS, Eckert RL., Free PMC Article | 05/28/2022 |
The Role of Transglutaminase 2 in the Radioresistance of Melanoma Cells. | The Role of Transglutaminase 2 in the Radioresistance of Melanoma Cells. Aepler J, Wodtke J, Wodtke R, Haase-Kohn C, Löser R, Pietzsch J, Hauser S., Free PMC Article | 05/7/2022 |
[Transglutaminase 2 inhibits the proliferation of H1 subtype influenza virus in MDCK cells]. | [Transglutaminase 2 inhibits the proliferation of H1 subtype influenza virus in MDCK cells]. Guo S, Liao Y, Qiu Z, Liu G, Wang J, Yang D, Zhang J, Qiao Z, Ma Z, Li Z, Liu Z. | 04/9/2022 |
Role of TGM2 in Tcell lymphoblastic lymphoma via regulation of IL6/JAK/STAT3 signalling. | Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling. Wang Y, Zheng N, Sun T, Zhao H, Chen Y, Liu C., Free PMC Article | 04/2/2022 |
Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. | Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. Aguiari G, Crudele F, Taccioli C, Minotti L, Corrà F, Keillor JW, Grassilli S, Cervellati C, Volinia S, Bergamini CM, Bianchi N., Free PMC Article | 04/2/2022 |
High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels. | High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels. Urick ME, Yu EJ, Bell DW., Free PMC Article | 03/12/2022 |